Mar. 17 at 2:27 PM
$RZLT I can't envision any scenario where FDA says "start over from scratch and do a brand new cHI phase 3 study."
I think worst case scenario is they amend the protocol for the ongoing study and initiate a randomized withdrawal phase. It would be idiotic to NOT leverage the ongoing OLE.
I suspect the recent drop was just some fund cashing out to take advantage of some other opportunity. The stock did go from <
$1.50 to close to
$4. That's a massive gain, so there will definitely be investors who are happy to take the 2-3X and avoid any risk.
I hold LONG until the biology is clear. I think in the end, ersodetug will prove to be an effective and well-used drug in multiple indications.
